RxDoctor Payments Data

Alan Yao, MD

Gastroenterology · Flushing, NYNPI 1053325647

Payments from drug & device makers

$50,663in general payments, 2019–2025

Across 162 payments — averaging $312.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$49K
  • Intra-sana Laboratories$492
  • AbbVie$195
  • Insmed, Inc.$125
  • Amgen$120
  • Lilly USA, LLC$109
  • plus $291 from 6 others

What the payments were for

  • Speaking & faculty fees$45,44090%
  • Travel & lodging$6091%
  • Food & beverage$4,2618%
  • Education$530%
  • Gifts$3001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,663 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$114,196
Medicare patients
289
Services billed
1,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide130$194,559
EntyvioVedolizumab17$155,683
CreonLipase/Protease/Amylase46$93,090
RemicadeInfliximab13$50,458
FarxigaDapagliflozin Propanediol33$25,668
VascepaIcosapent Ethyl36$16,855
Ursodiol224$15,877
LinzessLinaclotide27$14,609
Omeprazole1,340$13,562
Sucralfate250$13,241
Mesalamine60$12,785
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates206$12,542
Entecavir71$11,172
Budesonide ErBudesonide13$10,412
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate11$6,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$49,331$194,559130 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$21$155,68317 claims
AbbVieCreon, Linzess$195$107,69973 claims
Johnson & JohnsonRemicade$103$50,45813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →